1
40
2
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ajem.2021.05.001" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ajem.2021.05.001</a>
ISSN
1532-8171
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<a href="http://neomed.idm.oclc.org/login?url=http://doi.org/10.1016/j.ajem.2021.05.001" target="_blank" rel="noreferrer noopener">NEOMED Full-text Holding (if available) - Proxy DOI: 10.1016/j.ajem.2021.05.001</a>
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Update Year & Number
May 2021 List
NEOMED College
NEOMED College of Medicine
NEOMED Department
Department of Emergency Medicine
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination.
Publisher
An entity responsible for making the resource available
The American Journal Of Emergency Medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2021
2021-05-04
Subject
The topic of the resource
Vaccine; COVID-19; Thrombotic thrombocytopenia Purpura; TTP
Creator
An entity primarily responsible for making the resource
Yocum A; Simon EL
Description
An account of the resource
The U.S. Food and Drug Administration (FDA) recently issued an Emergency Use Authorization (EUA) for two highly effective Sars-CoV-2 (COVID-19) vaccines from Pfizer-BioNTech and Moderna. More recently, EUA was granted for the Johnson and Johnson COVID-19 vaccine which uses traditional virus-based technology. In this vaccine, researchers added the gene for the coronavirus spike protein to modified Adenovirus 26 and named it Ad26.COV2-S. Nearly 7 million doses of the Ad26.COV2-S have been administered as of mid-April 2021. Recently the Federal Drug Administration and Center for Disease Control and Prevention reviewed data involving six reported cases in the United States of cerebral venous sinus thrombosis in combination with thrombocytopenia in people who received the vaccination. All cases were in women between 18 and 48, with symptoms developing six to 13 days after vaccination. A recent study in the United Kingdom reported similar events in 23 patients age 21 to 77, 61% of which were female, with cases of presumed vaccine induced thrombosis and thrombocytopenia occurring six to 24 days after vaccination. We report a 62-year-old female who presented to the emergency department (ED) with acute onset of altered mental status. She had received the Ad26.COV2-S vaccine 37 days prior to ED presentation. She developed thrombotic thrombocytopenic purpura (TTP) and no other cause was found. To our knowledge this is the first case in the United States of thrombotic thrombocytopenic purpura after receiving the Ad26.COV2-S COVID-19 vaccine. (Copyright © 2021 Elsevier Inc. All rights reserved.)
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ajem.2021.05.001" target="_blank" rel="noreferrer noopener">10.1016/j.ajem.2021.05.001</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Format
The file format, physical medium, or dimensions of the resource
journalArticle
2021
COVID-19
Department of Emergency Medicine
journalArticle
May 2021 List
NEOMED College of Medicine
Simon EL
The American journal of emergency medicine
Thrombotic thrombocytopenia Purpura
TTP
Vaccine
Yocum A
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Articles Published in 2021
Creator
An entity primarily responsible for making the resource
Shelley Harrell
Publisher
An entity responsible for making the resource available
Shelley Harrell
Date
A point or period of time associated with an event in the lifecycle of the resource
2021
Description
An account of the resource
Items published in 2021
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<table width="91" style="border-collapse:collapse;width:68pt;"><colgroup><col width="91" style="width:68pt;" /></colgroup><tbody><tr style="height:15pt;"><td width="91" height="20" class="xl18" style="width:68pt;height:15pt;"><a href="http://doi.org/10.1016/j.ajem.2021.05.001">http://doi.org/10.1016/j.ajem.2021.05.001</a></td>
</tr></tbody></table>
NEOMED College
NEOMED College of Medicine
NEOMED Department
Department of Emergency Medicine
Update Year & Number
Jan to Aug list 2021
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination.
Creator
An entity primarily responsible for making the resource
Yocum A; Simon EL
Publisher
An entity responsible for making the resource available
The American Journal Of Emergency Medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2021
2021-05-04
Description
An account of the resource
The U.S. Food and Drug Administration (FDA) recently issued an Emergency Use Authorization (EUA) for two highly effective Sars-CoV-2 (COVID-19) vaccines from Pfizer-BioNTech and Moderna. More recently, EUA was granted for the Johnson and Johnson COVID-19 vaccine which uses traditional virus-based technology. In this vaccine, researchers added the gene for the coronavirus spike protein to modified Adenovirus 26 and named it Ad26.COV2-S. Nearly 7 million doses of the Ad26.COV2-S have been administered as of mid-April 2021. Recently the Federal Drug Administration and Center for Disease Control and Prevention reviewed data involving six reported cases in the United States of cerebral venous sinus thrombosis in combination with thrombocytopenia in people who received the vaccination. All cases were in women between 18 and 48, with symptoms developing six to 13 days after vaccination. A recent study in the United Kingdom reported similar events in 23 patients age 21 to 77, 61% of which were female, with cases of presumed vaccine induced thrombosis and thrombocytopenia occurring six to 24 days after vaccination.
Subject
The topic of the resource
We report a 62-year-old female who presented to the emergency department (ED) with acute onset of altered mental status. She had received the Ad26.COV2-S vaccine 37 days prior to ED presentation. She developed thrombotic thrombocytopenic purpura (TTP) and no other cause was found. To our knowledge this is the first case in the United States of thrombotic thrombocytopenic purpura after receiving the Ad26.COV2-S COVID-19 vaccine.
Identifier
An unambiguous reference to the resource within a given context
<table width="91" style="border-collapse:collapse;width:68pt;"><colgroup><col width="91" style="width:68pt;" /></colgroup><tbody><tr style="height:15pt;"><td width="91" height="20" class="xl18" style="width:68pt;height:15pt;"><a href="http://doi.org/10.1016/j.ajem.2021.05.001">http://doi.org/10.1016/j.ajem.2021.05.001</a></td>
</tr></tbody></table>
Rights
Information about rights held in and over the resource
© 2021 Elsevier Inc. All rights reserved.
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2021
COVID-19
Thrombotic thrombocytopenia Purpura
TTP
Vaccine